

---

# Controllable Cell-Based Therapies: Regulatory Challenges & Opportunities

**Christopher A Bravery**

**[cbravery@advbiols.com](mailto:cbravery@advbiols.com)**


# Introduction

---


- Regulation of Healthcare products in the EU
- Medicines – what are they?
- How do new technologies find their place?
- Regulatory challenges and opportunities
  - for discussion

# Healthcare and related products: Legal Framework

---



# Healthcare and related products: How it works out...



# Directive 2001/83/EC

---

## 2. Medicinal product:

(a) Any substance or combination of substances presented as having properties for treating or preventing disease in human beings;

or

(b) Any substance or combination of substances which may be **used in or administered to human beings either with a view to restoring, correcting or modifying physiological functions by exerting a pharmacological, immunological or metabolic action**, or to making a medical diagnosis.

# Medical Devices

## Directive 93/42/EEC

---

*‘medical device’ means any instrument, apparatus, appliance, **material** or other article, whether used alone or in combination, including the software necessary for its proper application intended by the manufacturer to be used for human beings for the purpose of:*

- diagnosis, prevention, monitoring, treatment or alleviation of disease,*
- diagnosis, monitoring, treatment, alleviation of or compensation for an injury or handicap,*
- investigation, **replacement or modification of the anatomy or of a physiological process,***
- control of conception,*

*and which **does not** achieve its principal intended action in or on the human body by pharmacological, immunological or metabolic means, but which may be assisted in its function by such means;*

# What are the Objectives of Medicines Regulation?

---

- Safeguarding public health
  - Medicines can be dangerous
  - Unacceptable toxicity
  - Disease transmission (biological materials/medicines)
- Consumer protection
  - Fit for purpose
  - Learn from mistakes
- Consumer confidence
  - Knowing they are regulated.

# What are the Basic Requirements for Medicines?


---

- Quality
  - Consistent
  - Pure or few (and safe) levels of impurities
- Safety
  - Risks identified and mitigated as far as reasonable
  - Safety evaluated such that risks understood/controlled
- Efficacy
  - It works (when you follow the instructions) within the limitations stated.
  - Risk/benefit



# Risk/Benefit

---



- Toxicity/side effects
- Risk of disease transmission
- Treatment/cure of disease/symptoms
- Secondary benefits

# The Rest is Science

---

- Core Directives give definition and scope
- Technical Annexes gives high level data requirements (but not prescriptive)
- Regulatory guidelines are mandatory – but most are procedural
- Pharmacopoeia
  - monographs mandatory (give or take)
  - general chapters are guidance
- Scientific guidelines are just that
  - convey principles
  - reflect on agency experience to date
  - Nearly always ‘...*unless otherwise justified*’

# Regulatory Pathway

## What this means to Regulatory Professionals

---

- Legal framework
  - Which legal framework applies?
  - Medicine, device etc. (or >1)
- Legal basis for approval
  - Medicine
    - Full dossier
    - Abridged dossier
      - Generic, biosimilar etc
  - Medical Device
    - Implantable, IVD, active implantable etc
    - Class I, IIa, IIb, III.

# Regulatory Pathway

## What this means to Developers

---

- What do I need to do?
- Regulatory Translation:
  - **What are the Data Requirements?**

# Regulatory Pathway

## What are the Data Requirements?

---

- Depends on the science.
  - But you need to establish Q/S/E somehow
- The regulators will not have the answers at the beginning
  - Why? Because its new!
- What should I do?
  - Early discussion of new technology with regulators
    - Warning! Premature discussion can backfire
      - Scare the regulators
      - Confuse the regulators
      - Slow progress (uncertain if safe to proceed)
  - Consider early discussion with regulatory professionals

# Regulatory Pathway

## What are the Data Requirements?

---


- Depends on the science.
  - But you need to establish Q/S/E somehow
- Early pioneers need to work it out
  - Every medicine is case-by-case to some degree
  - Understand what you are trying to achieve
    - Asking basic questions of regulators will not make a good impression
    - make sure you understand the regulatory framework/s and principles
  - Formulate a plan to do this (several stages)
  - Discuss the plan with regulators
    - Only when you are certain it's a good plan
    - One step at a time

# CONCLUSIONS

---

- Current legal framework is logical and elegant
- Legal framework avoids specifics
- Specific scientific principles provided as guidelines
  - not prescriptive
  - easily updated
- Upside ‘considerable flexibility’
- Downside ‘moving target’
- Early adopters of new technology need to work with the regulators to figure out the data requirements.

# THANK YOU



**“You’re a selfish man, Lewis! Those stem-cell lines were meant for people who’ve LOST an organ!”**




# Back-up Slides

---

# Product Development

## Stages of Product Development



© 2010, Consulting on Advanced Biologicals Ltd

# Analogous approaches

